Patients with a large myocardial infarction
Conditions
Interventions
Trade Name: Byetta
Product Name: exenatide
Pharmaceutical Form: Suspension for injection
Sponsors
Erasmus MC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consecutive patients with a large Myocardial infarction are screened for inclusion in the trial. The eligibility criteria consist of the following: 1. Delay between onset of chest pain and PCI = 6 hours in case of inferiolateral wall infarction and = 12 hours in case of anterior wall infarction 2. Persistent ST-elevation on entry in the cath lab 3. Occluded (TIMI = 1) infarct related artery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Younger than 18 years of age 2. Chronic obstructive lung disease with evidence of bronchospasm 3. Concomitant use of dipyridamole / theophylline 4. Second/third degree heart block or sick sinus syndrome 5. Cardiogenic shock / post cardiac resuscitation 6. Thrombolytic therapy in the previous week 7. Pre-excisting heart failure 8. History of known previous myocardial infarction, CABG 9. Any contraindication for MRI, i.e.: 10. Serious known concomitant disease with a life expectancy of less than one year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to determine whether ischemic postconditioning with or without pharmacological glycemic control is superior to the standard care given in PCI and whether these effects are acute or chronic.;Secondary Objective: VOLGT VOLGT;Primary end point(s): Infarct size measured on delayed enhance (DE) MRI at 4 months. | — |
Countries
Netherlands
Outcome results
None listed